Efficacy of Interleukin-2 in Triple Negative Breast Cancer
NCT05821686
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Triple Negative Breast Cancer
Interventions
DRUG:
Human Interleukin-2 (IL-2) (Proleukin)
Sponsor
Nova Scotia Health Authority